Merial Limited

Merial Sas

Other

Boehringer Ingelheim Animal Health USA Inc.

Chulalongkorn University

University of Saskatchewan

The Queen's University of Belfast

Catherine Elisabeth Charreyre

John R Harding

John Ellis

Gilles Emile Chappuis

Brian Martin Meehan

Francis McNeilly

Lori Hassard

Edward Clark

Deborah Haines

Gordon Moore Allan

Andrew A Potter

Lorne A Babiuk

Philip J Willson

Li Wang

Jean-Christophe Francis Audonnet

Stephanie Marie-Catherine Desgouilles-Blechet

Alexis Guy Andre Parisot

Michel Joseph Bublot

Jennifer Maria Perez

Jules Maarten Minke

Teshome Mebatsion

George Krakowka

George Steve Krakowka

Gordon Allan Moore

Francis Jean-Christophe Audonnet

Claude Jean Marie Roulet

Sanipa Suradhat

Robert M Nordgren

Alexis Guy Parisot

John Harding

Gordon Allan

Brian Meehan

Déborah Haines

Michel Bublot

The present invention provides vectors that contain and express in vivo or in vitro one or more Hendra virus polypeptides or antigens that elicit an immune response in animal or human against Hendra virus and Nipah virus, compositions comprising said vectors and/or Hendra virus polypeptides, methods of vaccination against Hendra virus and Nipah virus, and kits for use with such methods and compositions.

Hendra virus recombinant compositions and uses thereof

The invention provides novel methods and compositions for the vaccination of porcine animals against porcine reproductive and respiratory syndrome virus (PRRSV). Described herein are immunological and/or vaccine compositions comprising a DNA vector encoding a PRRSV protein, particularly a truncated ORF7 protein, which are administered to porcines using needle-free delivery. The plasmid can include more than one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions.

Needle-free administration of PRRSV vaccines

The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.

Postweaning multisystemic wasting syndrome and porcine circovirus from pigs

The present invention relates to oil-in-water emulsions, their use as adjuvants, and pharmaceutical, immunologic, or vaccine compositions that may comprise the same. In one embodiment, the oil-in-water (O/W) emulsion may comprise an aqueous solution containing an immunogen, a mineral oil, a non-ionic lipophilic ethoxylated fatty alcohol and a non-ionic hydrophilic surfactant. In another embodiment, the oil-in-water (O/W) emulsion may comprise an aqueous solution containing an immunogen, a non-ionic lipophilic surfactant, a mineral oil and a non-ionic hydrophilic ethoxylated fatty alcohol. The present invention also encompasses a method of making a vaccine composition using the adjuvant of the instant invention, the vaccine composition so obtained and methods of use.

Vaccine formulations

The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group comprising an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.

Provided is a method for reducing viral load of porcine circovirus type 2 (PCV-2) in a pig by inducing an immune response against PCV-2 through the administration of an immunogenic composition comprising a PCV-2 antigen. A preferred antigen is a vector containing a PCV-2 nucleotide sequence. In a particularly preferred embodiment, the PCV-2 nucleotide sequence is ORF4, ORF13, or ORF4 and ORF13. In some embodiments, the immunogenic composition includes one or more additional pig pathogens.

Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2

The invention relates to new porcine circovirus strains isolated from pulmonary or ganglionic samples obtained from farms affected by the post-weaning multisystemic wasting syndrome (PMWS). It relates to purified preparations of these strains, conventional attenuated or inactivated vaccines, recombinant live vaccines, plasmid vaccines and subunit vaccines, as well as reagents and diagnostic methods. It also relates to the DNA fragments which can be used for the production of subunits in an in vitro expression vector or as sequences to be integrated into a virus or plasmid type in vivo expression vector.

Porcine circoviruses, vaccines and diagnostic reagents

The invention relates to immunogenic preparations or vaccines comprising, on the one hand, a plasmid encoding and expressing a gene from PCV, in particular selected from the group consisting of ORF1 of PCV-2, ORF2 of PCV-2, ORF1 of PCV-1 and ORF2 of PCV-1, and, on the other hand, an element capable of increasing the immune response directed against the product of expression of the gene, which can be a carbomer, a porcine cytokine, e.g. GM-CSF or a cationic lipid of formulain which Ris a saturated or unsaturated linear aliphatic radical having from 12 to 18 carbon atoms, Ris another aliphatic radical comprising from 2 to 3 carbon atoms, andt X is an hydroxyle ou amine group. The cationic lipid can be DMRIE, possibly coupled with DOPE.

DNA vaccine-PCV

Porcine circovirus-2 (PCV-2) is a recently identified agent wherein the potential spectrum of PCV-2-associated disease has been expanded by evidence of vertical and sexual transmission and associated reproductive failure in swine populations. PCV-2 was isolated from a litter of aborted piglets from a farm experiencing late term abortions and stillbirths. Severe, diffuse myocarditis was present in one piglet associated with extensive immunohistochemical staining for PCV-2 antigen. Variable amounts of PCV-2 antigen were also present in liver, lung and kidney of multiple fetuses. Inoculation of female pigs with a composition including an immunogen from PCV-2 or an epitope of interest from such an immunogen or with a vector expressing such an immunogen or epitope of interest prior to breeding, such as within the first five weeks of life, or prior to the perinatal period, or repeatedly over a lifetime, or during pregnancy, such as between the 6 and 8 and/or the 10 and 13 weeks of gestation, can prevent myocarditis, abortion and intrauterine infection associated with porcine circovirus-2. In addition, innoculation of male and/or female pigs with the aforementioned compositions can be carried out to prevent transmission of PCV-2 from male to female (or vice versa) during mating. Thus, the invention involves methods and compositions for preventing myocarditis, abortion and intrauterine infection associated with porcine circovirus-2.

Reduction of porcine circovirus-2 viral load with inactivated PCV-2

Growing community of inventors

Saint-Laurent de Mure, France

Catherine Elisabeth Charreyre